参考资料（上下滑动查看全部）：

[1]Jing Pan, Kaiting Tang, Yuechen Luo, Samuel Seery, Yue Tan, Biping Deng, Feng Liu, Xiuwen Xu, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Chunyu Li, Kai Wang, Yibing Zhang, Xinjian Yu, Qinlong Zheng, Liping Zhao, Jiecheng Zhang, Alex H Chang, Xiaoming Feng,Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study,The Lancet Oncology,Volume 24, Issue 11,2023,Pages 1229-1241, ISSN 1470-2045

[2]Autologous CD7 CAR T-Cell Therapy for Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma,JSH2023

[3]Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia，Journal of Hematology & Oncology

[4]供者来源CD5 CAR-T细胞治疗急性T淋巴细胞白血病（T-ALL）的研究（S116），EHA2023